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BACKGROUND: Several human cancers have been found to contain cancer stem-like cells (CSCs) having cancer-initiating ability.
However, only a few reports have shown the existence of CSCs in bone and soft tissue sarcomas. In this study, we identified and
characterised side population (SP) cells that showed drug-resistant features in human bone sarcoma cell lines.
METHODS: In seven osteosarcoma cell lines (OS2000, KIKU, NY, Huo9, HOS, U2OS and Saos2) and in one bone malignant fibrous
histiocytoma (MFH) cell line (MFH2003), the frequency of SP cells was analysed. Tumourigenicity of SP cells was assessed in vitro and
in vivo. Gene profiles of SP cells and other populations (main population; MP) of cells were characterised using cDNA microarrays.
RESULTS: SP cells were found in NY (0.31%) and MFH2003 (5.28%). SP cells of MFH2003 formed spherical colonies and re-populated
into SP and MP cells. In an NOD/SCID mice xenograft model, 1 10
3 sorted SP cell-induced tumourigenesis. cDNA microarray
analysis showed that 23 genes were upregulated in SP cells.
CONCLUSIONS: We showed that SP cells existed in bone sarcoma cell lines. SP cells of MFH2003 had cancer-initiating ability in vitro and
in vivo. The gene profiles of SP cells could serve as candidate markers for CSCs in bone sarcomas.
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Over the past three decades, there have been remarkable advances
in the treatment of bone and soft tissue sarcomas. These include
the introduction of adjuvant chemotherapy, establishment of
guidelines for adequate surgical margins and the development of
post-excision reconstruction (Fletcher et al, 2002; Lewis, 2007).
However, the prognosis of non-responders to chemotherapy is still
poor and the mechanisms of tumourigenesis of bone and soft
tissue sarcomas remain to be demonstrated.
Generally, cancer masses are considered to be a complex of
heterogeneous but equally malignant cell populations. However,
recent stem cell research on the development of normal organs has
drawn attention to the existence of a ‘cancer stem-like cell (CSC)’
counterpart, which is characterised by its self-renewal capacity,
differentiation potential, and cancer-initiating ability (Visvader
and Lindeman, 2008). On the basis of these characteristics, CSCs
have been postulated to be responsible for driving the growth of
tumours and for the recurrence of neoplasms after current
therapeutic modalities are used.
Initial attempts to characterise CSCs were accomplished using
cell surface molecules in acute myeloid leukaemia. Several groups
that found CSCs capable of initiating leukaemia were found in the
CD34
þCD38
  fraction (Warner et al, 2004). Recently, CSCs have
been isolated from several human solid tumours that have markers
for putative normal stem cells, including breast cancer
(CD44
þCD24
 ESA
þ) (Al-Hajj et al, 2003), pancreatic cancer
(CD44
þCD24
 ESA
þ, CD133
þCXCR4
þ) (Hermann et al, 2007;
Li et al, 2007), brain cancer (CD133
þ) (Singh et al, 2004), prostate
cancer (CD44
þ/a2b1
hi/CD133
þ) (Collins et al, 2005), hepatocellular
carcinoma (CD133
þ) (Yin et al, 2007) and colon cancer (CD133
þ)
(Ricci-Vitiani et al, 2007).
On the other hand, in the analysis of haematopoietic stem cells,
a sub-population that effluxes the DNA-binding dye Hoechst 33342
out of the cell membrane through an ATP-binding cassette (ABC)
transporter was recognised as a stem cell population (Goodell et al,
1996; Zhou et al, 2002; Robinson et al, 2005). This cell population
expressing the ABC transporter was defined as side population
(SP) cells, which were distinguished from cells of the other
population (main population; MP). Recent studies demonstrated
that SP cells could be characterised as CSCs in primary tissues of
gastrointestinal cancers (Haraguchi et al, 2006) and ovarian cancer
(Szotek et al, 2006). SP cells were also shown in established tumour
cell lines with different origins, such as glioma (Kondo et al, 2004),
breast (Kruger et al, 2006) and thyroid cancer monoclonal cell
lines (Mitsutake et al, 2007).
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sTo date, however, distinct molecular markers on CSCs are still
lacking in many cancers. Moreover, only a few reports have shown
the existence of CSCs in bone and soft tissue sarcomas (Gibbs et al,
2005; Wu et al, 2007; Tirino et al, 2008). In this study, with the goal
of determining specific markers of CSCs, we identified and
characterised SP cells having cancer-initiating ability in osteo-
sarcoma and bone malignant fibrous histiocytoma cell lines.
MATERIALS AND METHODS
Cell lines and culture
Seven human osteosarcoma (OS) cell lines (OS2000, KIKU, NY,
Huo9, HOS, U-2OS and Saos2) and one bone human malignant
fibrous histiocytoma (MFH) cell line (MFH2003) were used.
OS2000, KIKU and MFH2003 were established in our laboratory
(Wada et al, 1988; Nabeta et al, 2003; Tsukahara et al, 2006). The
other cell lines were kindly donated by or purchased from the
Japanese Collection of Research Bioresources Cell Bank (Tokyo,
Japan) and from the American Type Culture Collection (Manassas,
VA, USA). MFH2003 and OS2000 were cultured with Iscove’s
modified Dulbecco’s Eagle’s medium (IMDM; GIBCO BRL, Grand
Island, NY, USA) containing 10% FBS and the others were
maintained in Dulbecco’s modified Eagle’s medium (DMEM;
Sigma-Aldrich, St Louis, MO, USA) containing 10% FBS in a 5%
CO2 incubator at 371C.
Identification of side population
Cell suspensions were labelled with dye Hoechst 33342 (Cambrex
Bio Science Walkersville Inc., MD, USA) using the methods
described by Goodell et al (1996) with some modifications . Briefly,
cells were trypsinised and re-suspended in pre-warmed DMEM
supplemented with 5% FBS at a concentration of 1 10
6ml
 1.
Hoechst33342 dye was added at a final concentration of 2.5 or
5.0mgml
 1 in the presence or absence of verapamil (50 or 75mM;
Sigma-Aldrich) as an inhibitor of the ABC transporter. The cells
were incubated at 371C for 90min with continuous shaking. At the
end of the incubation, the cells were washed with ice-cold PBS with
5% FBS, centrifuged at 41C and resuspended in ice-cold PBS
containing 5% FBS. Propidium iodide (at a final concentration of
1mgml
 1; Molecular Probes–Invitrogen, Eugene, OR, USA) was
used to gate viable cells. Flow cytometry and cell sorting were
performed using FACSVantage SE (BD Biosciences, Bedford, MA,
USA), EPICS ALTRA (Beckman-Coulter, Fullerton, CA, USA) and
FACS Aria II (BD Biosciences). The Hoechst 33342 dye was excited
at 357nm and its fluorescence was analysed using dual wave-
lengths (blue, 402–446nm; red, 650–670nm).
RNA preparation
Total RNAs were extracted from SP cells and MP cells using the
RNeasy Mini kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. Using an Amino Allyl MessageAmp
aRNA Kit Ver. 2 (Sigma-Aldrich Japan, Ishikari, Japan), amino
allyl-modified aRNAs were prepared from total RNAs from SP and
MP cells as previously described (Takeuchi et al, 2008).
Real-time PCR analysis
Total RNA was reverse transcribed using the SuperScriptIII reverse
transcriptase enzyme (Invitrogen) according to the manufacturer’s
instructions. Real-time PCR was performed with SYBR Green Real-
time Core Reagent (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions on an ABI Prism 7900
Sequence Detection System (Applied Biosystems). Primers were
designed to generate a PCR product of o200bp. The thermal
cycling conditions were 941C for 2min, followed by 35 cycles of
15s at 941C, 30s at 601C and 30s at 721C. Levels of expression were
normalised to the glyceraldehyde-3-phosphate dehydrogenase
(G3PDH) housekeeping gene.
Spherical colony formation assay
Spherical colony formation assay was performed as described by
Gibbs et al (2005) with some modifications. Briefly, cells were plated
at 2000 cells per well in six-well ultra-low attachment plates (Corning
Inc., Corning, NY, USA). Mesenchymal Stem Cell Basal Medium
(MSCBM) and MSCBM SingleQuots (Takara Bio Inc., Ohtsu,
Japan) were used for cell culture. Fresh aliquots of epidermal
growth factor and basic fibroblast growth factor were added every
other day. On day 14, the numbers of colonies were counted.
Xenograft model
Sorted SP and MP cells of MFH2003 were collected and
re-suspended at 1 10
2–1 10
5 cells per 50ml of PBS, followed
by addition of 50ml of Matrigel (BD Biosciences). This cell-
Matrigel suspension was subcutaneously injected into the backs of
4- to 6-week-old non-obese diabetic/severe combined immuno-
deficiency (NOD/SCID) mice (NOD.CB17-Prdkc
scid/J, Charles
River Laboratory, Yokohama, Japan) under anaesthesia. Mice
were observed for up to 12 weeks.
Gene expression profiling using cDNA microarrays
The aRNAs from SP cells were labelled with Cy5 dye and those
from MP cells were labelled with Cy3 dye. The dye-labelled aRNA
samples were hybridised to a 29138-spot Human Panorama Micro
Array (Sigma-Aldrich) for 16h at 451C. The intensities of Cy5 and
Cy3 fluorescence for every gene spot on the hybridised array were
measured with a GenePix 4000B scanner (Axon Instrument,
Austin, TX, USA), and were analysed with GenePix Pro 5.0
software (Axon Instrument). Global normalisation of the resultant
data was carried out using Excel 2004 (Microsoft, Redmond, WA,
USA). As a result, 24730 genes were available for further analysis.
The average expression ratio of Cy5 to Cy3 was obtained for each
gene. A dye-swap experiment (labelling SP and MP cells with Cy3
and Cy5, respectively) was also performed. An average ratio of
more than 2.0, reproducible in two experiments, was determined to
indicate differential upregulation in SP cells.
RESULTS
Identification of SP cells in human bone sarcoma cell lines
To identify the CSCs of bone sarcomas, we tried to detect side
population (SP) cells in bone and soft tissue sarcoma cell lines. As
depicted in Figure 1A, the NY and MFH2003 cell lines included
0.38 and 5.28% SP cells, respectively. In each case, the percentage
of SP cells was markedly diminished by treatment with verapamil,
which is an inhibitor of the pumps responsible for the exclusion of
Hoechst dye, indicating that this population truly represented SP
cells. SP cells were hardly detected in the other cell lines
(Figure 1B). Therefore, MFH2003, containing the highest propor-
tion of SP cells, was selected and further analysed.
Isolation of SP cells and their repopulation as both SP and
MP cells
After excluding dead cells and cellular debris on the basis of scatter
signals and propidium iodide fluorescence, MFH2003 cells were
sorted into SP and MP cells. As shown in Figure 2A, the G1 gate
showed the SP cells that had negative/low patterns of staining with
Hoechst 33342, and the G2 gate showed the main population cells
that were positively stained with Hoechst 33342. To ascertain the
SP cells in bone sarcoma cell lines
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spurity of sorted cells, the obtained SP (G1) cells and MP (G2) cells
were re-analysed. The purity levels were 92.86 and 90.78% in the
SP population and MP population, respectively. These results
supported the specificity for further analysis using the resultant SP
and MP cells.
To examine whether SP cells could generate both SP and MP
cells, sorted SP and MP cells were further cultured in vitro. On day
14, the cells were re-stained with Hoechst 33342 and analysed by
flow cytometry. We observed that SP cells re-populated both SP
and MP cells. The ratio of SP cells to MP cells was still much higher
than that before sorting. In contrast, SP cells were not detected in
sorted MP cells.
Expression of ABCG2 mRNA, which is a marker of SP cells, was
increased in SP cells (Figure 2B). These results also supported the
specificity for further characterisation of SP cells, especially with
regard to their cancer-initiating ability.
Spherical colony formation
We next evaluated the ability of SP and MP cells to generate
spherical colonies. A total of 2000 SP and MP cells were sorted and
cultured immediately under conditions of serum starvation,
providing an anchorage-independent environment. On day 14,
SP cells showed spherical colony formation (Figure 3A). On the
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Figure 1 Detection of side population cells in bone sarcoma cell lines. (A) The populations of SP cells of seven osteosarcoma cell lines (NY, OS2000,
KIKU, Huo9, HOS, Saos2 and U2OS) and of one bone MFH cell line (MFH2003), in the presence or absence of verapamil, are shown. SP cells are marked by
black dotted lines to show the proportion of SP cells among total living cells. (B) The mean proportions of SP cells in cell lines. These results were
reproducible in at least two independent experiments.
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sother hand, as shown in Figure 3B, most MP cells died and the
others formed a few small colonies. We removed spherical colonies
from the suspension culture and attempted again to determine
whether the cells could attach to a substratum. As shown in
Figure 3C, cells were seen expanding from the sphere. In
Figure 3D, the number of colonies is shown, indicating clearly
that, among MFH2003 cells, SP, but not MP, cells had the potential
for spherical colony formation.
Cancer-initiating ability of SP and MP cells in vivo
To address the issue of whether tumourigenic activity differed
between SP and MP cells, 1 10
2–1 10
5 SP and MP cells sorted
from MFH2003 were injected into NOD/SCID mice (Figure 4A). To
rule out the effects of the toxicity of Hoechst, we routinely
performed (i) depletion of dead cells by PI staining and (ii) a
viability check using trypan-blue staining after cell sorting. Almost
all MP cells were viable as SP cells. Subcutaneous tumour
formation was induced by the injection of 1 10
3 SP cells
(Table 1). We also observed that 1 10
4 SP cells formed a larger
tumour mass than did 1 10
3 SP cells (data not shown). In
contrast, at least 1 10
5 MP cells were required to give rise to a
tumour. Macroscopic and microscopic findings of a tumour
derived from SP cells are shown in Figure 4A and B. These results
supported the hypothesis that SP cells have a high cancer-initiating
ability, similar to CSCs. At 8 weeks after xenotransplantation, the
frequencies of SP and MP cells in a formed tumour derived from
1 10
4 SP cells were analysed ex vivo. SP cells were hardly detected
in the tumour. Most SP cells re-populated into MP cells in vivo in 8
weeks (data not shown).
Identification of upregulated genes in SP cells
Finally, we performed gene expression profiling of SP cells
using cDNA microarrays. As shown in Table 2, 23 genes were
found to be upregulated in SP cells, compared with MP cells.
Although the functions of upregulated genes varied, these
results suggested that the factors connected to DNA transcription,
transport of substrates, cell proliferation and apoptosis might have
a role in the cancer-initiating ability of SP cells. In addition, the
increased expression of ABCG2 in SP cells confirmed the accuracy
of the gene expression profiling analysis.
DISCUSSION
In this study, we showed that (i) small SP populations existed in
one osteosarcoma cell line and one bone MFH cell line; (ii) SP cells
derived from MFH2003 could re-populate both SP and MP cells in
vitro; (iii) SP cells could form spherical colonies and re-populate
into SP and MP cells; (iv) SP cells had tumourigenesis in an in vivo
xenograft model; and (v) factors regarding transcription, cell
proliferation and apoptosis were upregulated in SP cells.
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Figure 2 The re-population of SP cells into both SP and MP cells. (A)
(a) The populations of SP cells and MP cells before cell sorting are shown.
SP cells were gated as G1, and MP cells were gated as G2. (b, c) The
proportions of SP cells among the total living cells are indicated. Isolated SP
cells (b) and MP cells (c) after cell sorting. The proportions of SP and MP
cells among the total living cells are indicated. (d, e) The populations of SP
cells (d) and MP cells (e) after 2-week in vitro culture with medium
containing 10% FBS are also shown. Experiments were repeated in
triplicate with similar results. (B) The relative expression of ABCG2 was
evaluated in SP cells and MP cells by real-time PCR.
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sWe observed proportions of SP cells of 0.31 and 5.28% in NY
and MFH2003, respectively. The proportions of SP cells we
observed were similar to those in most previous reports, with
2% noted in human breast cancer cell line MCF7, 0.4% in rat C6
glioma, 1.2% in human HeLa carcinoma (Kondo et al, 2004) and
4–37% in neuroblastoma cell lines (Hirschmann-Jax et al, 2004).
The SP cells were defined by the efflux of Hoechst 33342, a cell-
permeable DNA-specific bisbenzimidazole dye, through an ABC
transporter. Therefore, SP cells are considered to be resistant to
multi-chemotherapeutic drugs and to confer malignant pheno-
types to tumours (Dean et al, 2005). Hence, the characterisation of
SP cells might be a useful tool for analysis of CSCs, especially when
specific CSC surface markers are unknown.
We found that SP cells could re-populate both SP cells and MP
cells in vitro. These results suggested that SP cells were capable of
self-renewal and also generated MP cells by asymmetric division.
This indicated that a tumour hierarchy might exist in bone MFH.
Previous studies have also shown that SP cells can divide
asymmetrically and display a capacity for self-renewal similar to
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Figure 3 Tumourigenesis of SP and MP cells in vitro.( A and B) The features of spherical colonies derived from resultant SP cells (A) and MP cells (B)
cultured without serum in an anchorage-independent manner for 2 weeks. (C) Spherical colony removed from the suspension culture and allowed to attach
to a substratum. Adherent cells can be seen expanding from the sphere. (D) The numbers of resultant spherical colonies from SP cells and MP cells were
counted. Data are representative of three independent experiments.
SP
50m
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Figure 4 The features of xenotransplanted SP cells in vivo.( A) Macroscopic features of 1 10
3 each of SP and MP cells in an NOD/SCID mouse at 12
weeks after xenotransplantation. Black arrow indicates the site of injection of MP cells. (B) Histological findings of the xenotransplanted tumour derived from
SP cells (1 10
4). Haematoxilin and eosin staining (original magnification:  200) is shown.
Table 1 Tumorigenesis of SP and MP cells in NOD/SCID mice
Cell number for injection
1 10
2 1 10
3 1 10
4 1 10
5
MFH2003
SP cells 0/5 1/5 2/5 1/2
MP cells 0/5 0/5 0/5 1/2
SP and MP cells were isolated separately and injected into the backs of the
subcutaneous space of NOD/SCID mice. Tumour formation was observed for 12
weeks after injection.
SP cells in bone sarcoma cell lines
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snormal stem cells (Kondo et al, 2004; Singh et al, 2004). On the
other hand, we also observed that most SP cells xenotransplanted
in NOD/SCID mice re-populated into MP cells in vivo. SP cells
might hardly be maintained in vivo for long time, that is, more
than 8 weeks. In other words, the niche of the mouse model might
not be adequate for the maintenance of SP cells derived from bone
sarcoma cell lines, such as MFH2003.
The ability of SP cells to generate spherical colonies was higher
than that of MP cells. This is consistent with previous studies
(Patrawala et al, 2005; Mitsutake et al, 2007). We recognised that
the difference was not a consequence of longer retention of
Hoechst dye in MP cells, because MP cells were viable after
staining with the dye, followed by sorting and maintenance in a
culture medium with FBS. However, we cannot completely rule out
the possibility that the difference was due to some effect of the
Hoechst dye, which is potentially cytotoxic (Durand and Olive,
1982).
We could detect a higher tumourigenic potential of SP cells than
of MP cells in vivo using a NOD/SCID xenograft model. In the field
of bone and soft tissue sarcoma, only Wu et al (2007) succeeded in
showing the in vivo cancer-initiating ability of CSCs derived from
bone and soft tissue sarcomas, using SP cells isolated from fresh
primary tumour tissues. The ability to consistently isolate
MFH2003-derived SP cells allowed us to conduct SP cell-specific
gene profiling. Moreover, it might become possible to identify
CTL-defined CSC-specific tumour antigens for immunotherapy
targeting CSCs. Thus far, we have been trying to identify CTL-
defined tumour antigens by forward and reverse immunological
approaches and have carried out antigenic peptide vaccination
trials in bone and soft tissue sarcomas (Sato et al, 2002; Ida et al,
2004; Tsukahara et al, 2004, 2008a,b, 2009; Kawaguchi et al, 2005;
Kimura et al, 2008). Currently, we are trying to establish
autologous CTL clones recognising SP cells of MFH2003 from
tumour-infiltrating lymphocytes.
Thus far, only Oct3/4, Nanog and CD133 were reported to be
candidates for CSC-specific markers in bone and soft tissue
sarcoma (Gibbs et al, 2005; Tirino et al, 2008). Therefore, the gene
profile of SP cells might help to expand the possibility of an
effective isolation of CSCs from bone and soft tissue sarcomas
using these specific markers. In the current gene expression
profiling, 23 genes with various functions were upregulated in SP
cells. Among them, eight genes (VPF, c20orf14, MCL1, NR4A2,
IRX3, NRLP12, PTN and LMNA) might be considered to be
potential tumourigenic factors in malignancies. VPF, generally
known as vascular endothelial growth factor, regulates vascular
permeability, angiogenesis, cell migration and apoptosis in
tumours (Nagy et al, 2008). C20orf14 is upregulated in lymphoma
(Su et al, 2008) and HPV16/18-positive cervical cancer (Vazquez-
Ortiz et al, 2007). MCL1 is a member of the B-cell lymphoma (BCL)
family. MCL-1 negatively regulates pro-apoptotic factors (Bak and
Bax) (Chen et al, 2007) and accelerates leukaemogenesis (Beverly
and Varmus, 2009). NR4A2 belongs to the steroid nuclear
hormone receptor superfamily and has a role in cell transforma-
tion in cervical cancer (Ke et al, 2004). IRX3 is epigenetically
inactivated by methylation in CpG islands in brain tumours
(Ordway et al, 2006) and prostate cancer (Morey et al, 2006).
NLRP12, also known as RNO2/monarch-1, is reported to activate
inflammation in humans (Ye et al, 2008). PTN is an angiogenic
factor that stimulates tumour-associated vascular formation in
many malignancies. (Perez-Pinera et al, 2008). LMNA is reported
to encode lamin A, which is a putative colonic epithelial stem cell
marker and is also a prognostic factor in colorectal cancer (Willis
et al, 2008). On the other hand, four genes (ANKRD11, PHLDA3,
APOL1 and MSX1) are known as tumour-suppressor factors.
ANKRD11 is a p53-interacting protein and activates the transcrip-
tion of p53 in breast cancer. PHLDA3 is a positive regulator of Fas-
dependent death signalling, related to cisplatin-mediated apoptosis
(Kerley-Hamilton et al, 2005). APOL1 is classically thought to be
involved in lipid transport and metabolism and has rarely been
characterised with regard to cell survival. Although the structure of
APOL1 is similar to that of the anti-apoptotic proteins of the Bcl-2
family (Vanhollebeke and Pays, 2006), it can induce autophagic
cell death (Wan et al, 2008). MSX1, a homeobox gene important
for embryonic neural crest development, can induce the inhibition
of tumour-initiating ability in soft agar in vitro. Taken together,
the gene expression profiling in SP cells derived from MFH2003
containing various tumour-proliferative and tumour-suppressive
factors might indicate the complexity of maintaining the
Table 2 List of genes upregulated in SP cells of MFH2003
Expression ratio (SP/MP)
Gene symbol Gene name Accession no. Gene ontology Cy5/Cy3 Cy3/Cy5
ANKRD11 Ankyrin repeat domain 11 NM_013275 Electron transport 2.1 2.7
SLC2A4 Solute carrier family 2, member 4 NM_001042 Carbohydrate transport 2.2 2.5
KIAA1440 KIAA1440 AB037861 Unknown 2.2 3.3
SURF6 Surfeit 6 NM_006753 Ribosome biogenesis 2.3 2.8
VPF Vascular permeability factor M27281 Cell proliferation 3.0 3.5
C20orf14 Chromosome 20 open reading frame 14 NM_012469 RNA processing 2.1 3.6
PHLDA3 Pleckstrin homology-like domain, family A, member 3 NM_012396 Physiological processes 2.1 2.4
ZNF19 Zinc finger protein 19 NM_152907 Regulation of transcription 2.8 2.4
MCL1 Myeloid cell leukaemia sequence 1 NM_021960 Apoptosis 2.1 3.9
APOE Apolipoprotein E NM_000041 Lipid transport 2.1 3.8
NR4A2 Nuclear receptor subfamily 4, group A, member 2 NM_006186 Regulation of transcription 2.5 4.1
IRX3 Iroquois-related homeobox 3 BC023667 Regulation of transcription 3.3 2.9
GNB3 Guanine nucleotide-binding protein, b-polypeptide 3 NM_002075 G-protein coupled receptor protein signaling 2.1 5.0
NLRP12 NLR family, pyrin domain containing 12 NM_144687 Apoptosis 2.1 2.3
PTN Pleiotrophin NM_002825 Neurogenesis 2.0 2.6
ABCG2 ATP-binding cassette, sub-family G, member 2 NM_004827 Transport 2.2 2.9
APOL1 Apolipoprotein L NM_145343 Lipid transport 2.2 2.6
MDFI MyoD family inhibitor NM_005586 Unknown 2.8 3.1
PRSS15 Protease, serine, 15 NM_004793 ATP-dependent proteolysis 2.1 2.5
MSX1 Msh homeo box homolog 1 NM_002448 Regulation of transcription 2.1 2.8
LDLR Low density lipoprotein receptor NM_000527 Cholesterol metabolism 2.1 3.1
LMNA Lamin A/C NM_170707 Cellular morphogenesis 2.1 2.9
MVK Mevalonate kinase BC016140 Cholesterol biosynthesis 2.2 2.1
Genes showing the ratio more than 2.0, which were reproducible in two experiments, were listed.
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considering the characteristics of SP cells for cancer-initiating
ability, the apoptosis-related molecules among these genes
(MCL-1, ANKRD11, PHLDA3 and APOL1) might have roles in
the proliferation of SP cells. Moreover, these molecules could
be candidates for specific markers and, in addition, molecular
therapeutic targets.
In conclusion, we identified SP cells in established human bone
sarcoma cell lines. Moreover, we demonstrated that bone MFH-
derived SP cells can re-populate both SP and MP cells and have
cancer-initiating ability in vitro and in vivo. These findings
supported the idea that bone sarcomas might contain a certain
population of CSCs. Gene profiling of SP cells could serve to
elucidate candidates for specific markers and therapeutic targets.
Thus, further studies for the characterisation of CSCs in human
bone and soft tissue sarcomas might contribute to the elucidation
of the mechanisms of tumourigenesis and to the establishment of
novel therapeutic strategies.
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